Related Experiment Video

Updated: Jan 20, 2026

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
05:56

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

1.9K

Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients

Farha Sherani1, Catherine Boston2, Nkechi Mba2

  • 1Department of Pediatric Hematology & Oncology, Cancer & Blood Disorders Center, Driscoll Children's Hospital, 3533 S. Alameda St, Corpus Christi, TX, 78411, USA. farha.sherani@dchstx.org.

Current Oncology Reports
|August 17, 2019
PubMed

Insights

Pediatric chemotherapy-induced nausea and vomiting (CINV) guidelines now favor triple therapy, including a 5-HT3 antagonist, dexamethasone, and a neurokinin-1 antagonist, for improved prophylaxis. New data support aprepitant and palonosetron use.

Area of Science:

  • Pediatric oncology
  • Pharmacology
  • Clinical guideline development

Background:

  • Chemotherapy-induced nausea and vomiting (CINV) significantly affects children's quality of life during cancer treatment.
  • Evolving prophylaxis strategies are crucial for managing CINV in pediatric patients.

Purpose of the Study:

  • To review the evolution of CINV prophylaxis guidelines specifically for children.
  • To highlight recent literature, particularly from the last five years, shaping current recommendations.

Main Methods:

  • Literature review focusing on pediatric CINV prophylaxis.
  • Analysis of recent studies influencing guideline updates.
  • Examination of new antiemetic agents and risk stratification factors.

Main Results:

  • Triple therapy (5-HT3 antagonist, dexamethasone, NK1 antagonist) is now the recommended CINV prophylaxis backbone for children.
  • Aprepitant has been added to regimens, and palonosetron is recognized as a non-inferior 5-HT3 antagonist option.
  • Pediatric-specific data on patient risk factors and drug emetogenicity are increasingly informing guidelines.

Conclusions:

  • Recent pediatric studies have significantly updated CINV prophylaxis guidelines.
  • The current standard emphasizes a multi-drug approach tailored to pediatric cancer patients.
  • Continued research is vital for further refining CINV management in children.
Abstract

Keywords:
AntiemeticCINVChemotherapy-induced nausea and vomitingGuidelinesNauseaSupportive careVomiting

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

586
Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture05:33

Author Spotlight: Alleviating Nausea and Vomiting in Pregnancy with Safe and Effective Auricular Acupuncture

Published on: August 4, 2023

2.2K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
678
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
607
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
820
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
600
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.7K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214